Research and Development

The new era of personalised cancer care requires different thinking from pharma companies, according to experts at the ESMO symposium. …

There are signs that outsourcing in the pharmaceutical sector is staging a comeback after a couple of tough operating years, …

Our round-up of recent development in the contract research sector includes updates from Selcia, Iris Pharma, ICON, Proteome Sciences, Chiltern, …

Gilead’s HIV drug Truvada can help prevent men from contracting the disease through sexual intercourse, a new study shows.The clinical …

A new report on the spread of AIDS has called for the development of new pharma compounds that will lead …

Celldex will press ahead with large-scale trials of its vaccine treatment for brain cancer after encouraging phase II results. The …

I have just participated in a consultation by the Academy of Medical Sciences on the regulation and governance of clinical …

Phase III data for a new age-related macular degeneration (wet AMD) treatment show it is as good as Lucentis, the …

Pfizer’s axitinib has impressed in phase III trials assessing its efficacy as a second line treatment for renal cell carcinoma. …

Bayer has announced large scale job losses aimed at saving 800 million euro savings in the coming years.The cuts are …

BTG is to pay £156 million to acquire Biocompatibles, the drug-device specialists.Established in 1984 and floated in 1995, Biocompatibles specialises …

Novartis has outlined its long-term strategy for managing a number of key patent expiries. The Swiss-based pharma firm plans to …

Genzyme is in talks with Takeda to secure a ‘white knight’ bid that would prevent Sanofi-Aventis from taking over the …

Roche’s ‘Operational Excellence’ programme will see it cut 6% of its global workforce over the next two years. The initiative …

Pfizer has established a new network of research partnerships with its Global Centers for Therapeutic Innovation. The Centers is a …